TTFD/Allithiamine: The Fat-Soluble Thiamine That Gets Into the Brain

Ordinary vitamin B1 is water-soluble and relies on transporters that saturate above about 5 mg per dose, so most of a large oral dose is simply excreted; TTFD (“allithiamine”) and benfotiamine are fat-soluble forms that cross cell membranes by diffusion and convert back to thiamine inside the cell, raising intracellular levels that plain thiamine cannot reach. TTFD is the form that crosses into the brain and has been used in conditions where the brain struggles to use thiamine, but that evidence is mostly case series and small open-label studies, with randomized data still limited; benfotiamine acts mainly in peripheral nerves and has a randomized trial (BENDIP) showing modest improvement in painful diabetic neuropathy. The most important practical caveat is that TTFD (typically 50–200 mg/day with a fat-containing meal) can trigger a temporary “paradoxical” worsening of fatigue or anxiety in the first 1–3 weeks, which starting low (10–25 mg) and titrating up usually avoids. Much of its marketed use in POTS, dysautonomia, and migraine runs ahead of the formal trial data.

Where TTFD comes from

TTFD was developed in Japan in the 1960s after researchers noticed that garlic and rice-bran extracts produced a longer-lasting thiamine effect than ordinary thiamine alone. The lipid-soluble disulfide form passes through cell membranes, including the blood–brain barrier, and is broken down inside cells to release free thiamine. In tissue and blood measurements, TTFD raises intracellular thiamine to levels that ordinary oral thiamine cannot reach (Lonsdale 2006; PMID 16550223).

Neurological uses

TTFD has been studied in conditions where the brain has trouble using thiamine: pyruvate dehydrogenase deficiency, subacute necrotizing encephalomyelopathy (Leigh syndrome), and a range of fatigue syndromes. Reports are mostly case series and small open-label studies, with randomized evidence still limited. Wider clinical use in dysautonomia, POTS, and migraine has run ahead of the formal trial data, so claims should be treated cautiously.

Benfotiamine: the diabetic-neuropathy cousin

Benfotiamine (S-benzoylthiamine O-monophosphate) is another fat-soluble thiamine derivative. It is best studied for painful diabetic neuropathy. The BENDIP randomized trial (Stracke 2008, Experimental and Clinical Endocrinology & Diabetes; PMID 18473286) tested benfotiamine 300–600 mg/day over 6 weeks and reported modest symptom improvement on the TSS pain score. Unlike TTFD, benfotiamine does not enter the brain efficiently — it acts mainly in peripheral nerves and tissues (Volvert 2008, BMC Pharmacology; PMID 18549472).

Dosing and caveats

TTFD is usually taken at 50–200 mg/day with a meal that contains some fat. Some users report a short-lived rough patch — worse fatigue or anxiety for 1–3 weeks — in the first weeks of use, which clinicians who use TTFD describe as a “paradoxical reaction.” Starting at 10–25 mg and slowly working up usually avoids this. TTFD is well tolerated long term but has a noticeable sulfur odor that some people dislike.